Loading…
Loading…
SRDX (Surmodics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
SRDX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SRDX and 80,000+ other tickers.
See exactly how SRDX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SRDX and 80,000+ other tickers.
Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility…
Surmodics, Inc. (NASDAQ: SRDX - Get Free Report) has been assigned an average rating of "Reduce" from the five brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating on the company. The average 1
Groupe la Francaise decreased its stake in Surmodics, Inc. (NASDAQ: SRDX) by 28.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,800 shares of the company's stock after selling 33,700 shares during the period. Groupe la Francaise
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the “Merger”) of the Company by an affiliate of GTCR LLC (“GTCR”) promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the “District Court”), the Feder.
The United States District Court for the Northern District of Illinois on Tuesday denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction that would have prevented the proposed acquisition of Surmodics Inc. (NASDAQ:SRDX) by GTCR.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR.